Registre observationnel de l’efficacité et de la tolérance de la capsaïcine 8 % (Qutenza®) dans les douleurs neuropathiques périphériques localisées pharmacorésistantes
Tóm tắt
Les douleurs neuropathiques localisées peuvent bénéficier d’un traitement par la capsaïcine 8 % après échec des thérapeutiques de première intention. L’objectif de l’étude était d’évaluer dans une population de patients pharmacorésistants, adressés sur 16 mois en CETD, l’efficacité du Qutenza®, sa tolérance, et d’identifier les facteurs prédictifs de réponse. Parmi les 61 patients analysés, 39 % étaient soulagés d’au moins 30 % à deux mois. Les signes cutanés observés ont toujours été transitoires. Le seul facteur prédictif négatif retrouvé était une allodynie sévère au froid.
Tài liệu tham khảo
Anand P, Bley K (2011) Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 107:490–502
Attal N (2012) Neuropathic pain: mechanisms, therapeutic approach, and interpretation of clinical trials. Contin Minneap Minn 18:161–75
Backonja MM, Malan TP, Vanhove GF, et al (2010) NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med 11:600–8
Backonja M, Wallace MS, Blonsky ER, et al (2008) NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 7:1106–12
Bouhassira D, Attal N, Fermanian J, et al (2004) Development and validation of the Neuropathic Pain Symptom Inventory. Pain 108:248–57
Brown S, Simpson DM, Moyle G, et al (2013) NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials. Aids Res Ther 10:5
Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23:129–38
England J, Wagner T, Kern KU, et al (2011) The capsaicin 8% patch for peripheral neuropathic pain. Br J Nurs 20:926–31
European Commission Approves New Pre-treatment Options for QUTENZA(TM) (8% Capsaicin Patch) in Peripheral Neuropathic Pain. 2013 Mar 14; Available from: http://www.presseportal.de/pm/61801/2433374/european-commission-approves-new-pretreatment-options-for-qutenza-tm-8-capsaicin-patch-in
Gustorff B (2012) Treatment of peripheral neuropathic pain with the capsaicin 8% patch: Is Quantitative Sensory Testing a useful tool to predict response to treatment? International congress IASP
Hoper J, Helfert S, Heskam ML, et al (2013) High concentration capsaicin for treatment of peripheral neuropathic pain: Effect on somatosensory symptoms and identification of treatment responders. Curr Med Res Opin [in press]
Irving GA, Backonja MM, Dunteman E, et al (2011) A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med 12:99–109
Irving GA, Backonja M, Rauck R, et al (2012) NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Clin J Pain 28:101–7
Kennedy WR, Vanhove GF, Lu SP, et al (2010) A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain 11:579–87
Maihofner C, Heskamp ML (2013) Prospective, noninterventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. Curr Med Res Opin 29:673–83
Martini CH, Yassen A, Krebs-Brown A, et al (2013) A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia. Eur J Pain 17:1491–501
Peppin JF, Majors K, Webster LR, et al (2011) Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain. J Pain Res 4:385–92
Ragé M, Van Acker N, Facer P, et al (2010) The time course of CO2 laser-evoked responses and of skin nerve fibre markers after topical capsaicin in human volunteers. Clin Neurophysiol 121:1256–66
Simpson DM, Brown S, Tobias J (2008) Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 70:2305–13
Simpson DM, Gazda S, Brown S, et al (2010) Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage 39:1053–64
Treede RD, Wagner T, Kern KU, et al (2013) Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain. Curr Med Res Opin 29:527–38
Webster LR, Malan TP, Tuchman MM, et al (2010) A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. J Pain 11:972–82
Webster LR, Tark M, Rauck R, et al (2010) Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia. BMC Neurol 10:92